TITLE:
Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival
AUTHORS:
B. E. Cham
KEYWORDS:
BEC, Solamargine, Cisplatin, Curaderm, Anti-Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.8,
August
18,
2020
ABSTRACT: Plant-derived BEC with its main component solamargine
possesses anticancer activities via its effect on a variety of biological
pathways in a wide range of human cancer cells. High cure rates with BEC
therapy have been obtained in animals with deadly cancers, and, in humans with
terminal cancers promising results have been reported. At a clinical level,
optimal concentrations of BEC have been established in a topical cream
formulation Curaderm, for effective removal of skin cancers, but optimal
concentrations of BEC have not been reported for other cancers. The objective
of this study was to determine whether combination therapy of Cisplatin with
BEC would result in synergism using cure rates as end points. BEC on its own
cures Sarcoma 180 in mice, whereas, Cisplatin on its own has no effect on Sarcoma
180 activity. A combination of BEC and Cisplatin shows synergism, resulting in
higher cure rates than BEC and Cisplatin at comparable individual
concentrations.